[1]Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies \[J\]. Nat Rev Endocrinol, 2017, 13(11): 644-660.
\[2\]Mohebati A, Dilorenzo M, Palmer F, et al. Anaplastic thyroid carcinoma: a 25year singleinstitution experience \[J\]. Ann Surg Oncol, 2014, 21(5): 1665-1670.
\[3\]Jiao C, Li L, Zhang P, et al. REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radiotherapeutic response by regulating the Smad7TGFβ pathway \[J\]. Cell Death Differ, 2020, 27(2): 497-508.
\[4\]Ma Y, Cang S, Li G, et al. Integrated analysis of transcriptome data revealed MMP3 and MMP13 as critical genes in anaplastic thyroid cancer progression \[J\]. J Cell Physiol, 2019, 234(12): 22260-22271.
\[5\]Hao Z, Wang P. Lenvatinib in management of solid tumors \[J\]. Oncologist, 2020, 25(2): e302-e310.
\[6\]Capdevila J, Wirth LJ, Ernst T, et al. PD1 blockade in anaplastic thyroid carcinoma \[J\]. J Clin Oncol, 2020, 38(23): 2620-2627.
\[7\]Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019 \[J\]. CA Cancer J Clin, 2019, 69(1): 7-34.
\[8\]Haddad RI, Nasr C, Bischoff L, et al. Nccn guidelines insights: thyroid carcinoma, version 2.2018 \[J\]. J Natl Compr Canc Netw, 2018, 16(12): 1429-1440.
\[9\]Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries \[J\]. CA Cancer J Clin, 2018, 68(6): 394-424.
\[10\]Saini S, Tulla K, Maker AV, et al. Therapeutic advances in anaplastic thyroid cancer: a current perspective \[J\]. Mol Cancer, 2018, 17(1): 154.
\[11\]Aldinger KA, Samaan NA, Ibanez M, et al. Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid \[J\]. Cancer, 1978, 41(6): 2267-2275.
\[12\]Nel CJ, Van Heerden JA, Goellner JR, et al. Anaplastic carcinoma of the thyroid: a clinicopathologic study of 82 cases \[J\]. Mayo Clin Proc, 1985, 60(1): 51-58.
\[13\]Nagaiah G, Hossain A, Mooney CJ, et al. Anaplastic thyroid cancer: a review of epidemiology, pathogenesis, and treatment \[J\]. J Oncol, 2011, 2011: 542358.
\[14\]Smallridge RC, Copland JA. Anaplastic thyroid carcinoma: Pathogenesis and emerging therapies \[J\]. Clin Oncol (R Coll Radiol), 2010, 22(6): 486-497.
\[15\]Landa I, Ibrahimpasic T, Boucai L, et al. Genomic and transcriptomic hallmarks of poorly differentiated and anaplastic thyroid cancers \[J\]. J Clin Invest, 2016, 126(3): 1052-1066.
\[16\]Amin MB, Greene FL, Edge SB, et al. The eighth edition ajcc cancer staging manual: continuing to build a bridge from a populationbased to a more “personalized” approach to cancer staging \[J\]. CA Cancer J Clin, 2017, 67(2): 93-99.
\[17\]Lamartina L, Grani G, Arvat E, et al. 8th edition of the AJCC/TNM staging system of thyroid cancer: what to expect (ITCO#2) \[J\]. Endocr Relat Cancer, 2018, 25(3): L7-L11.
\[18\]周东辉, 钭赉振, 朱小桦,等. 未分化甲状腺癌的靶向和免疫治疗研究进展 \[J\]. 浙江医学,2020,42(18):1903-1908.
\[19\]Ahmed S, Ghazarian MP, Cabanillas ME, et al. Imaging of anaplastic thyroid carcinoma \[J\]. AJNR Am J Neuroradiol, 2018, 39(3): 547-551.
\[20\]Cabanillas ME, Mcfadden DG, Durante C. Thyroid cancer \[J\]. Lancet, 2016, 388(10061): 2783-2795.
\[21\]DeekenDraisey A, Yang GY, Gao J, et al. Anaplastic thyroid carcinoma: an epidemiologic, histologic, immunohistochemical, and molecular singleinstitution study \[J\]. Hum Pathol, 2018, 82: 140-148.
\[22\]Pezzi TA, Mohamed ASR, Sheu T, et al. Radiation therapy dose is associated with improved survival for unresected anaplastic thyroid carcinoma: outcomes from the national cancer data base \[J\]. Cancer, 2017, 123(9): 1653-1661.
\[23\]Kwon J, Kim BH, Jung HW, et al. The prognostic impacts of postoperative radiotherapy in the patients with resected anaplastic thyroid carcinoma: a systematic review and metaanalysis \[J\]. Eur J Cancer, 2016, 59: 34-45.
\[24\]Amaral M, Afonso RA, Gaspar MM, et al. Anaplastic thyroid cancer: how far can we go? \[J\]. Excli J, 2020, 19: 800-812.
\[25\]Melo M, Da Rocha AG, Vinagre J, et al. Tert promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas \[J\]. J Clin Endocrinol Metab, 2014, 99(5): E754-765.
\[26\]Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma \[J\]. Cell, 2014, 159(3): 676-690.
\[27\]Kunstman JW, Juhlin CC, Goh G, et al. Characterization of the mutational landscape of anaplastic thyroid cancer via wholeexome sequencing \[J\]. Hum Mol Genet, 2015, 24(8): 2318-2329.
\[28\]Jeon MJ, Chun SM, Kim D, et al. Genomic alterations of anaplastic thyroid carcinoma detected by targeted massive parallel sequencing in a BRAF(V600E) mutationprevalent area \[J\]. Thyroid, 2016, 26(5): 683-690.
\[29\]Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene \[J\]. Cancer Res, 2011, 71(13): 4403-4411.
\[30\]Murugan AK, Bojdani E, Xing M. Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer \[J\]. Biochem Biophys Res Commun, 2010, 393(3): 555-559.
\[31\]Zhu G, Xie L, Miller D. Expression of microRNAs in thyroid carcinoma \[J\]. Methods Mol Biol, 2017, 1617: 261-280.
\[32\]Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways \[J\]. Cancer Cell, 2016, 29(4): 452-463.
\[33\]Zhou Q, Chen J, Feng J, et al. Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroidstimulating hormone receptor (TSHR) \[J\]. Tumour Biol, 2016, 37(3): 3105-3113.
\[34\]Wang XM, Liu Y, Fan YX, et al. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway \[J\]. Cancer Biol Ther, 2018, 19(7): 590-597.
\[35\]Huang JK, Ma L, Song WH, et al. LncRNAMALAT1 promotes angiogenesis of thyroid cancer by modulating tumorassociated macrophage FGF2 protein secretion \[J\]. J Cell Biochem, 2017, 118(12): 4821-4830.
\[36\]Borbone E, Troncone G, Ferraro A, et al. Enhancer of zeste homolog 2 overexpression has a role in the development of anaplastic thyroid carcinomas \[J\]. J Clin Endocrinol Metab, 2011, 96(4): 1029-1038.
\[37\]Gunda V, Cogdill AP, Bernasconi MJ, et al. Potential role of 5aza2′deoxycytidine induced MAGEA4 expression in immunotherapy for anaplastic thyroid cancer \[J\]. Surgery, 2013, 154(6): 1456-1462.
\[38\]Hou P, Bojdani E, Xing M. Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways \[J\]. J Clin Endocrinol Metab, 2010, 95(2): 820-828.
\[39\]Mcfadden DG, Vernon A, Santiago PM, et al. P53 constrains progression to anaplastic thyroid carcinoma in a Brafmutant mouse model of papillary thyroid cancer \[J\]. Proc Natl Acad Sci U S A, 2014, 111(16): E1600-E1609.
\[40\]Knauf JA, Sartor MA, Medvedovic M, et al. Progression of BRAFinduced thyroid cancer is associated with epithelialmesenchymal transition requiring concomitant MAP kinase and TGFβ signaling \[J\]. Oncogene, 2011, 30(28): 3153-3162.
\[41\]Li LC, Jayaram S, Ganesh L, et al. Knockdown of MADD and cFLIP overcomes resistance to TRAILinduced apoptosis in ovarian cancer cells \[J\]. Am J Obstet Gynecol, 2011, 205(4): 362 e312-e325.
\[42\]Milosevic Z, Pesic M, Stankovic T, et al. Targeting RASMAPKERK and PI3KAKTmTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma \[J\]. Transl Res, 2014, 164(5): 411-423.
\[43\]Byeon HK, Na HJ, Yang YJ, et al. CMetmediated reactivation of PI3K/AKT signaling contributes to insensitivity of BRAF(V600E) mutant thyroid cancer to BRAF inhibition \[J\]. Mol Carcinog, 2016, 55(11): 1678-1687.
\[44\]Zhong Z, Hu Z, Jiang Y, et al. Interleukin11 promotes epithelialmesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/AKT/GSK3β signaling pathway activation \[J\]. Oncotarget, 2016, 7(37): 59652-59663.
\[45\]The Lancet. Breast cancer targeted therapy: successes and challenges \[J\]. Lancet, 2017, 389(10087): 2350.
\[46\]Lieu CH, Corcoran RB, Overman MJ. Integrating biomarkers and targeted therapy into colorectal cancer management \[J\]. Am Soc Clin Oncol Educ Book, 2019, 39: 207-215.
\[47\]Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments \[J\]. Lancet, 2017, 389(10066): 299-311.
\[48\]Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer \[J\]. N Engl J Med, 2013, 368(7): 684-685.
\[49\]Xin Y, Bai Y, Jiang X, et al. Sulforaphane prevents angiotensin Ⅱinduced cardiomyopathy by activation of Nrf2 via stimulating the Akt/GSK3β/Fyn pathway \[J\]. Redox Biol, 2018, 15: 405-417.
\[50\]Baldini E, D′armiento M, Ulisse S. A new aurora in anaplastic thyroid cancer therapy \[J\]. Int J Endocrinol, 2014, 2014: 816430.
\[51\]Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma \[J\]. Thyroid, 2014, 24(2): 232-240.
\[52\]Catalano MG, Pugliese M, Gallo M, et al. Valproic acid, a histone deacetylase inhibitor, in combination with paclitaxel for anaplastic thyroid cancer: results of a multicenter randomized controlled phase Ⅱ/Ⅲ trial \[J\]. Int J Endocrinol, 2016, 2016: 2930414.
\[53\]Mehta A, Zhang L, Boufraqech M, et al. Carfilzomib is an effective anticancer agent in anaplastic thyroid cancer \[J\]. Endocr Relat Cancer, 2015, 22(3): 319-329.
\[54\]Wunderlich A, Roth S, Ramaswamy A, et al. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer \[J\]. Endocrine, 2012, 42(3): 637-646.
\[55\]French JD, Bible K, Spitzweg C, et al. Leveraging the immune system to treat advanced thyroid cancers \[J\]. Lancet Diabetes Endocrinol, 2017, 5(6): 469-481.
\[56\]Caillou B, Talbot M, Weyemi U, et al. Tumorassociated macrophages (TAMS) form an interconnected cellular supportive network in anaplastic thyroid carcinoma \[J\]. PLoS One, 2011, 6(7): e22567.
\[57\]Bastman JJ, Serracino HS, Zhu Y, et al. Tumorinfiltrating T cells and the PD1 checkpoint pathway in advanced differentiated and anaplastic thyroid cancer \[J\]. J Clin Endocrinol Metab, 2016, 101(7): 2863-2873.
\[58\]Chintakuntlawar AV, Rumilla KM, Smith CY, et al. Expression of PD1 and PDL1 in anaplastic thyroid cancer patients treated with multimodal therapy: results from a retrospective study \[J\]. J Clin Endocrinol Metab, 2017, 102(6): 1943-1950.
\[59\]Brauner E, Gunda V, Vanden Borre P, et al. Combining braf inhibitor and anti PDL1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer \[J\]. Oncotarget, 2016, 7(13): 17194-17211.
\[60\]Kollipara R, Schneider B, Radovich M, et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer \[J\]. Oncologist, 2017, 22(10): 1149-1151.
\[61\]Zwaenepoel K, Jacobs J, De Meulenaere A, et al. Cd70 and PDL1 in anaplastic thyroid cancerpromising targets for immunotherapy \[J\]. Histopathology, 2017, 71(3): 357-365.
\[62\]Zhu L, Li XJ, Kalimuthu S, et al. Natural killer cell (NK92MI)based therapy for pulmonary metastasis of anaplastic thyroid cancer in a nude mouse model \[J\]. Front Immunol, 2017, 8: 816.
\[63\]Allegri L, Baldan F, Mio C, et al. Effects of BP14, a novel cyclindependent kinase inhibitor, on anaplastic thyroid cancer cells \[J\]. Oncol Rep, 2016, 35(4): 2413-2418.
\[64\]Abdulghani J, Gokare P, Gallant JN, et al. Sorafenib and quinacrine target antiapoptotic protein MCL1: a poor prognostic marker in anaplastic thyroid cancer (ATC) \[J\]. Clin Cancer Res, 2016, 22(24): 6192-6203.
\[65\]Ball DW, Jin N, Xue P, et al. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer \[J\]. Oncol Rep, 2015, 34(5): 2319-2324.
\[66\]Vanden Borre P, Gunda V, Mcfadden DG, et al. Combined BRAF(V600E)and SRCinhibition induces apoptosis, evokes an immune response and reduces tumor growth in an immunocompetent orthotopic mouse model of anaplastic thyroid cancer \[J\]. Oncotarget, 2014, 5(12): 3996-4010.
\[67\]Chin LH, Hsu SP, Zhong WB, et al. Combined treatment with troglitazone and lovastatin inhibited epidermal growth factorinduced migration through the downregulation of cysteinerich protein 61 in human anaplastic thyroid cancer cells \[J\]. PLoS One, 2015, 10(3): e0118674.
\[68\]IngesonCarlsson C, MartinezMonleon A, Nilsson M. Differential effects of MAPK pathway inhibitors on migration and invasiveness of BRAF(V600E) mutant thyroid cancer cells in 2D and 3D culture \[J\]. Exp Cell Res, 2015, 338(2): 127-135.
|